BioCryst Pharmaceuticals Inc (BCRX) Financials
Key financial figures for BioCryst Pharmaceuticals Inc (Q2 2026).
- Revenue
- $218M
- Net Income
- $78M
- EPS
- $0.31
- Total Assets
- $558M
- Operating Cash Flow
- $104M
Full income statement, balance sheet, and cash flow for BioCryst Pharmaceuticals Inc on SentiSense.